Stay updated on Adjuvant Nivo/Ipi for Melanoma Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Nivo/Ipi for Melanoma Clinical Trial page.

Latest updates to the Adjuvant Nivo/Ipi for Melanoma Clinical Trial page
- Check2 days agoChange DetectedThe page displays the ClinicalTrials.gov record for the Phase 2 melanoma study of adjuvant nivolumab and low-dose ipilimumab, including its treatment plan, eligibility criteria, outcomes, and study documents.SummaryDifference44%

- Check9 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check16 days agoChange DetectedA sitewide NIH notice appears, announcing transition updates and stating that some NIH content will use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI).SummaryDifference1%

- Check23 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check51 days agoChange DetectedA 403 Forbidden error page is now displayed, replacing the study record details with a generic error message and basic site chrome; this indicates access to the study record is blocked.SummaryDifference17%

Stay in the know with updates to Adjuvant Nivo/Ipi for Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Nivo/Ipi for Melanoma Clinical Trial page.